Advertisement

Search Results

Advertisement



Your search for Alice T. Shaw, MD, PhD matches 3 pages

Showing 1 - 3


lung cancer
issues in oncology

Crizotinib Highly Active in ROS1-Rearranged NSCLC

In a study reported in The New England Journal of Medicine, Shaw et al found that crizotinib (Xalkori) produced a high response rate in patients with ROS1-rearranged non–small cell lung cancer (NSCLC). Chromosomal rearrangements in ROS1, which encodes the proto-oncogene receptor tyrosine...

lung cancer
issues in oncology

ALK Rearrangements Are Associated With Improved Outcomes in Patients With Non‒Small Cell Lung Cancer and Brain Metastases

Compared with mutations in EGFR, KRAS, or with patients with no known mutations, ALK rearrangements were independently associated with improved survival outcomes in patients with non–small cell lung cancer (NSCLC) who received radiotherapy for brain metastases, according to the results of a...

lung cancer
issues in oncology

Ceritinib Highly Active in Patients With ALK-Rearranged Advanced NSCLC, Including Those With Prior Crizotinib Treatment

Non–small cell lung cancer (NSCLC) harboring ALK rearrangement is sensitive to the ALK inhibitor crizotinib (Xalkori), but resistance ultimately occurs. In a phase I study reported in The New England Journal of Medicine, Shaw et al found that the more-potent ALK inhibitor ceritinib was...

Advertisement

Advertisement



Advertisement